Seattle Genetics Drug Passes Safety Test, Trial Continues

Xconomy Seattle — 

Seattle Genetics said today its experimental drug for acute myeloid leukemia passed an interim safety review. The Bothell, WA-based biotech company (NASDAQ: SGEN) said an independent monitoring committee recommended the study continue of lintuzumab (SGN-33). Full results from the trial, which is two-thirds of the way to its enrollment goal of 210 patients, should be available in the first half of 2010, the company said.